Educational Framework
The Metabolic Disease Continuum
Metabolic conditions are frequently described as discrete diagnoses, but they often share underlying mechanisms — insulin resistance, ectopic fat accumulation, chronic low-grade inflammation, and disordered lipid handling — and can progress along a continuum over years.
From insulin resistance to type 2 diabetes
Insulin resistance often develops silently. The pancreas initially compensates by increasing insulin output, keeping blood glucose in range. Over time, beta-cell function may decline, fasting and postprandial glucose begin to rise, and a person progresses through impaired fasting glucose and impaired glucose tolerance — collectively termed prediabetes — to type 2 diabetes. Progression is not inevitable: lifestyle change and certain medications have been shown in randomized trials to delay or prevent it.1
Liver involvement (MASLD/MASH)
Excess hepatic fat — now called metabolic dysfunction–associated steatotic liver disease (MASLD), previously NAFLD — is closely tied to insulin resistance and abdominal adiposity. A subset of patients progress to metabolic dysfunction–associated steatohepatitis (MASH, formerly NASH), fibrosis, and in some cases cirrhosis. MASLD also increases cardiovascular risk independently of other factors.2
Cardiovascular disease
The same biology that drives insulin resistance — atherogenic dyslipidemia, hypertension, endothelial dysfunction, inflammation — also drives atherosclerosis. This is why metabolic syndrome is associated with two-to-three times the risk of cardiovascular events compared with metabolically healthy individuals.
Why "continuum" matters
Framing these conditions as a continuum has practical consequences. First, screening for one component (e.g., abnormal waist circumference) is an opportunity to evaluate others. Second, interventions that address upstream mechanisms — modest weight loss, improved physical activity, sleep, and in some cases medication — frequently improve multiple endpoints simultaneously. Third, progression is not deterministic; many patients improve markers with sustained intervention, and some achieve remission of type 2 diabetes after substantial weight loss.3
What this does not mean
The continuum is a useful conceptual model, not a prediction for any individual. People differ in genetics, environment, and trajectory. Some develop type 2 diabetes without overt obesity; others maintain stable metabolic markers despite elevated BMI. Care decisions should be made with a qualified clinician based on personal history, risk factors, and goals.
References
- Knowler WC, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM. 2002.
- Rinella ME, et al. A multisociety Delphi consensus on a new fatty liver disease nomenclature. Hepatology. 2023.
- Lean MEJ, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT). Lancet. 2018.